Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merrimack Pharmaceuticals Inc (NQ: MACK )

14.76 +0.03 (+0.21%)
Streaming Delayed Price Updated: 10:54 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,736
Open 14.73
Bid (Size) 14.76 (6)
Ask (Size) 14.77 (6)
Prev. Close 14.73
Today's Range 14.73 - 14.77
52wk Range 11.53 - 15.89
Shares Outstanding 14,400,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merrimack Receives $225 Million Milestone Payment from Ipsen
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Pharmaceuticals Inc. (NASDAQ: MACK) Highlighted for Surprising Price Action
Via Investor Brand Network

Performance

YTD
+10.90%
+10.90%
1 Month
+0.21%
+0.21%
3 Month
+10.90%
+10.90%
6 Month
+21.08%
+21.08%
1 Year
+21.28%
+21.28%

More News

Read More
MACK Stock Earnings: Merrimack Pharmaceuticals Reported Results for Q4 2023
Via InvestorPlace
Merrimack Reports Full Year 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
$2M Bet On Ford? Check Out These 4 Stocks Insiders Are Buying
Via Benzinga
Merrimack Reports Third Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Pancreatic Cancer Battle Boosted by $200M VC Firm
Via FinancialNewsMedia
Topics Death
Exposures Death
Merrimack Reports Second Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Merrimack Reports First Quarter 2023 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Why Jounce Therapeutics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Via InvestorPlace
Luna Innovations, Guess? And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Merrimack Reports Full Year 2022 Financial Results
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
3 Stocks Insiders Are Buying: Triumph Financial And More
Via Benzinga
$2.6M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Insiders Buying Heska, B. Riley Financial And 2 Other Stocks
Via Benzinga
$1.4 Million Bet On Joint Corp? Check Out These 3 Stocks Insiders Are Buying
Via Benzinga
Merrimack Pharmaceuticals Extends Section 382 Net Operating Loss Rights Plan
From Merrimack Pharmaceuticals, Inc.
Via Business Wire
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer
Via FinancialNewsMedia
Topics Death
Exposures Death
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
Via FinancialNewsMedia
Why Merrimack Pharmaceuticals Shares Jumped Around 213%; Here Are 114 Biggest Movers From Yesterday
Via Benzinga
Nasdaq Drops 200 Points; Meta Platforms Shares Jump
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why RumbleON Shares Are Trading Higher By Around 28%? Here Are 84 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.